AT A GLANCE Founded Feb 2000 IPO Sep 2003 Tokyo Stock Exchange - Mothers Code 2369 Capitalization 2,176 million yen* Market Cap 1,538 million yen* Issued Shares 203,442 shares* Headquarters Tokyo, JAPAN Representative Yasuhiro Hashimoto, M.D. President & CEO Group Companies MediBIC Pharma, Co., Ltd. MediBIC Co., Ltd. Site Quality Co., Ltd. Asia Private Equity Capital, Co., Ltd. Customers 20+ major pharmaceutical companies, research institutes and universities Mission Realizing Personalized Medicine *as of Jun 30, 2011 MediBIC Group is a Japan-based biotechnology company specializing pharmacogenomics (PGx). We provide solution services to develop therapies that improve human life. More than 20 major pharmaceutical companies, as MediBIC's corporate customers, have been able to benefit from faster time to market and substantially lower costs for drug development. In 2004 MediBIC started offering genetic testing services for individuals, leveraging our expertise and experiences in PGx business. All of our services support our core mission: Realizing Personalized Medicine. 2010 Financial Highlights: Ordinary loss was significantly reduced 58% to 257 million yen, mainly due to strong results in our Biomarker Drug Discovery business and successful sale of investment securities, as well as reduction of cost in the Personalized Health Management Support business. MediBIC conducted a private placement of the share purchase warrants allocated in November, 2010 and has raised over 1.9 million yen as of July 30, 2011. The going concern paragraph has been removed from its audit opinion contained in the recently filed annual report for the year ended December 31, 2010. MediBIC is comprised of three business segments: The Biomarker Drug Discovery We provide broad range of solution services for new drug development, including PGx project planning, sample collection arrangement, sample logistic, sample banking, DNA/RNA extraction and analysis, and data analysis for biomarker discovery for drug development. We also offer development support products through partnership with leading suppliers with innovative technologies overseas. MediBIC's sample banking facility is located in Translational Research Informatics Center (TRI), a state of the art storage center founded by Japanese government and Kobe City. This special privilege is granted as part of a collaborative research program between MediBIC and Foundation for Biomedical Research and Innovation. Personalized Healthcare Management Support "Genetic Testing for Drug Response" is a DNA screening test designed for individuals to find out if his/her genetics will affect excessive response to some drugs. We market this test mainly through clinics and dispensing pharmacies. We also offer a test especially designed for newborn babies to obstetricians. Cancer Drug Development MediBIC has been co-developing Glufosfamide, a novel small molecule with promising activity in several cancer types, with US-based Threshold Pharmaceuticals, Inc. Phase 3 international randomized trial will be commenced in mid 2011 under a Special Protocol Assessment (SPA) agreed with FDA by Eleison Pharmaceuticals, Inc., to which Threshold licensed Glufosfamide in 2009. NIH awarded research grants in November 2010 in support of late stage drug development of Glufosfamide for pancreatic cancer. The European Medicines Agency (EMA) also recommended the approval of Glufosfamide for Orphan Drug Designation in Europe. MediBIC Group, Co., Ltd. Dai2 Shiba Bldg. 3F, 27-2 Sakuragaoka-cho, Shibuya-ku, Tokyo 150-0031 JAPAN Tel: +81-3-6415-4032 Fax: +81-3-6415-4034 www.medibic.com